肿瘤细胞治疗研究
英文原题：Cell-based immunotherapy in oesophageal cancer.
食管癌（EC）是全球最常见的疾病之一，其预后不佳。
食管癌（EC）是全球最常见的疾病之一，其预后不佳。手术、放疗和化疗是EC的主要治疗选择。尽管这些传统治疗方式偶尔有效，但EC患者仍面临局部复发和转移的显著风险。因此，需要创新且有效的药物。近几十年来，临床实践已有效实施细胞疗法，包括基于干细胞和非干细胞的方案，作为一种创新的肿瘤治疗手段，为食管鳞状细胞癌（ESCC）患者带来了新的希望。本文探讨了EC患者细胞治疗的理论框架和当代进展。我们进一步描述了当前的临床研究，并总结了与生存率和安全性评估相关的关键数据。
Oesophageal cancer (EC) is among the most common illnesses globally, and its prognosis is unfavourable. Surgery, radiotherapy and chemotherapy are the primary therapy options for EC. Despite the occasional efficacy of these traditional treatment modalities, individuals with EC remain at a significant risk for local recurrence and metastasis. Consequently, innovative and efficacious medicines are required. In recent decades, clinical practice has effectively implemented cell therapy, which includes both stem cell and non-stem cell-based approaches, as an innovative tumour treatment, offering renewed hope to patients with oesophageal squamous cell carcinoma (ESCC). This paper examines the theoretical framework and contemporary advancements in cell treatment for individuals with EC. We further described current clinical studies and summarised essential data related to survival and safety assessments.
MEMBER ACCOUNT
登录成功会直接打开下一页。
